Document is current

Article History

Received: 15 July 2024

Accepted: 28 August 2024

First Online: 16 November 2024

Declarations

:

: T. Kato has received honoraria for lectures from MSD. J. Furukawa has received honoraria for lectures from Merck and Ono Pharmaceutical. N. Hinata has received honoraria for lectures from AstraZeneca, Bayer Yakuhin, Bristol Myers Squibb, Kissei Pharmaceutical, MSD, Sanofi, Sysmex, and Takeda. K. Ueda has received honoraria for lectures from Merck and MSD. I. Hara has received honoraria for lectures from Astellas Pharma, Janssen, and Takeda and has received research funding from Bristol Myers Squibb. F. Hongo has received honoraria for lectures from Merck, MSD, Pfizer, and Takeda. R. Mizuno has received honoraria for lectures from Merck and Takeda. T. Okamoto and H. Okuno have nothing to disclose. T. Ito and M. Kajita report employment with Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA. M. Oya has received honoraria from Bayer, Bristol Myers Squibb, Eisai, Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA, MSD, Ono Pharmaceutical, Pfizer, and Takeda; and has received scholarship endowments from Bayer, Eisai, and Takeda. Y. Tomita has participated in consulting or advisory roles for Eisai, MSD, and Ono Pharmaceutical; has received honoraria from Astellas Pharma, Bristol Myers Squibb Japan, Chugai Pharma, Novartis, Ono Pharmaceutical, and Pfizer; and has received research funding from Astellas Pharma, AstraZeneca, Chugai Pharma, Eisai, MSD, Novartis, Ono Pharmaceutical, Pfizer, and Takeda. N. Shinohara has received grants or contracts from Bristol Myers Squibb, Ono Yakuhin, and Takeda; has received honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Bristol Myers Squibb, MSD, Novartis, Ono Yakuhin, Pfizer, and Takeda; and is the president of the Japanese Society of Renal Cancer. M. Eto has received research funding from Takeda Pharmaceutical; and has received honoraria for lectures from Astellas Pharma, AstraZeneca, Bayer Yakuhin, Bristol Myers Squibb, Eisai, Janssen Pharmaceutical, Merck Biopharma, MSD, Ono Pharmaceutical, Pfizer, and Takeda Pharmaceutical. H. Uemura has received research grants from Astellas, AstraZeneca, Janssen, Ono Pharmaceutical, Taiho, and Takeda; has received consulting fees from Ono Pharmaceutical and Sanofi; has received payment or honoraria for lectures and speakers’ bureaus from Bayer, Janssen, MSD, Pfizer, Sanofi, and Takeda; and has received payment for expert advisory testimony from AstraZeneca, Ono Pharmaceutical, and Sanofi.